Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (RCC). Although these TKIs are associated with similar survival outcomes, some differences have been reported in their safety profiles. In this work, traditional toxicological...
Main Authors: | Filipa Amaro, Carolina Pisoeiro, Maria João Valente, Maria de Lourdes Bastos, Paula Guedes de Pinho, Márcia Carvalho, Joana Pinto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/17/9898 |
Similar Items
-
Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma
by: Filipa Amaro, et al.
Published: (2022-04-01) -
Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer
by: Daniel Evin, et al.
Published: (2024-02-01) -
Updates and Original Case Studies Focused on the NMR-Linked Metabolomics Analysis of Human Oral Fluids Part II: Applications to the Diagnosis and Prognostic Monitoring of Oral and Systemic Cancers
by: Martin Grootveld, et al.
Published: (2022-08-01) -
Pazopanib as first-line therapy for patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2018-07-01) -
Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators
by: Kim Westerdijk, et al.
Published: (2023-11-01)